导管消融与生活方式干预联合抗心律失常药物治疗房颤:PRAGUE-25试验
PRAGUE-25随机多中心非劣效性试验纳入212例肥胖(BMI 30-40 kg/m2)的阵发性或持续性房颤患者,1:1分配至导管消融组或生活方式干预联合抗心律失常药物组。12个月无房颤生存率消融组为73.0%,联合治疗组为34.6%(优效性P<0.001),消融显著优于联合治疗,尽管联合治疗组体重和HbA1c改善更明显。
要点
- 肥胖房颤患者导管消融12个月无房颤率73.0%,显著高于生活方式干预联合抗心律失常药物的34.6%。
- 生活方式干预联合抗心律失常药物组体重下降和HbA1c降低更显著,但未转化为房颤控制优势。
- 对于BMI 30-40 kg/m2的阵发性或持续性房颤患者,导管消融应作为优于生活方式干预联合抗心律失常药物的节律控制策略。
核心结论
- 在肥胖的阵发性或持续性房颤患者中,导管消融在12个月无房颤生存率方面优于生活方式干预联合抗心律失常药物。
研究设计与样本
- 随机多中心非劣效性试验,纳入212例BMI 30-40 kg/m2的阵发性或持续性房颤患者,1:1随机分配至导管消融组或生活方式干预联合抗心律失常药物组,最终203例纳入分析(导管消融组100例,联合治疗组103例)。
- 每3个月进行7天动态心电图监测,主要终点为随机化后12个月内无房颤(无持续时间>30秒的房颤发作),空白期为3个月。
主要发现
- 12个月无房颤患者比例导管消融组为73.0%(95%CI:64.3%-81.7%),联合治疗组为34.6%(95%CI:25.3%-43.9%),非劣效性P=0.99,优效性P<0.001。
- 联合治疗组体重变化为-6.4±7.9 kg,导管消融组为-0.35±4.8 kg(P<0.001),联合治疗组HbA1c降低更显著。
临床怎么用
- 对于BMI 30-40 kg/m2的阵发性或持续性房颤患者,导管消融可作为优于生活方式干预联合抗心律失常药物的节律控制选择。
- 生活方式干预带来的代谢改善(体重下降、HbA1c降低)未显著提高房颤无复发率,但仍可能具有整体健康获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is an important risk factor for atrial fibrillation (AF). Nonrandomized studies have shown that weight loss and increased physical activity are associated with AF reduction. OBJECTIVES: The goal of this study was to assess whether treatment based on lifestyle modification (LFM; directed weight loss and physical exercise) in combination with antiarrhythmic drugs (AADs) is noninferior to catheter ablation (CA) in patients with AF and obesity. METHODS: In a randomized multicenter noninferiority trial, we enrolled patients with paroxysmal or persistent AF and a body mass index (BMI) of 30-40 kg/m2. Patients were randomized to the CA vs LFM+AAD groups in a 1:1 ratio. Seven-day electrocardiographic Holter recordings were performed every 3 months. The primary endpoint was AF freedom during the 12 months after randomization (ie, absence of any AF episode lasting >30 s; the blanking period was 3 months). Secondary endpoints included AF burden, peak oxygen uptake during cardiopulmonary exercise testing, changes in metabolic parameters, and quality of life as assessed with the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire, all compared between randomization and 12 months. RESULTS: A total of 212 patients were enrolled and randomized. Nine patients withdrew consent, leaving 203 patients for the final analysis; 100 patients were allocated to the CA group and 103 to the LFM+AAD group (overall age 60 ± 9 years, 31.5% female, BMI 34.9 ± 3.0 kg/m2, 55.7% with paroxysmal AF); the mean follow-up time was 23.5 months. The percentage of patients with AF freedom at 12 months was 73.0% (95% CI: 64.3%-81.7%) in the CA group and 34.6% (95% CI: 25.3%-43.9%) in the LFM+AAD group (Pnoninferiority = 0.99, Psuperiority <0.001). Weight change (-6.4 ± 7.9 kg vs -0.35 ± 4.8 kg; P < 0.001) and decreased HbA1c, were more significant in the LFM+AAD group than in the CA group. CONCLUSIONS: Despite important metabolic improvements associated with LFM, CA was superior to LFM combined with AADs in improving freedom from AF at 1 year in patients with AF and obesity.
引用
- Osmancik P, Roubicek T, Havranek S, et al. Catheter Ablation vs Lifestyle Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation: PRAGUE-25 Trial. J Am Coll Cardiol. 2025. PMID: 40602939. doi:10.1016/j.jacc.2025.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。